Leon Kircik
About
In The Last Decade
Leon Kircik
325 papers receiving 4.1k citations
Hit Papers
Peers
Comparison fields: 5 of 127
- Dermatology 2.8k
- Immunology 1.4k
- Epidemiology 583
- Immunology and Allergy 568
- Cell Biology 431
Countries citing papers authored by Leon Kircik
This map shows the geographic impact of Leon Kircik's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Leon Kircik with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Leon Kircik more than expected).
Fields of papers citing papers by Leon Kircik
This network shows the impact of papers produced by Leon Kircik. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Leon Kircik. The network helps show where Leon Kircik may publish in the future.
Co-authorship network of co-authors of Leon Kircik
This figure shows the co-authorship network connecting the top 25 collaborators of Leon Kircik. A scholar is included among the top collaborators of Leon Kircik based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Leon Kircik. Leon Kircik is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 3 | |
| 2 | 1 | |
| 3 | 8 | |
| 4 | 2 | |
| 5 | 1 | |
| 6 | 1 | |
| 7 | 2 | |
| 8 | 4 | |
| 9 | 21 | |
| 10 | Real-World Evidence on the Use of Calcipotriene and Betamethasone Dipropionate Aerosol Foam 0.005%/0.064% in the Treatment of Psoriasis: A Review of Investigator-Initiated Studies Around the Globe. | 1 |
| 11 | Supplement Individual Article: A Reappraisal of Fixed-Combination Halobetasol Propionate and Tazarotene for the Treatment of Psoriasis: Biological Underpinnings, Therapeutic Mechanisms, and Economic Considerations. | 3 |
| 12 | 7 | |
| 13 | 8 | |
| 14 | A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle-Controlled Clinical Study to Compare the Safety and Efficacy of a Novel Tazarotene 0.045% Lotion and Tazarotene 0.1% Cream in the Treatment of Moderate-to-Severe Acne Vulgaris | 20 |
| 15 | Understanding topical therapies for psoriasis. | 2 |
| 16 | Assessing the Synergistic Effect of a Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion in Moderate-to-Severe Plaque Psoriasis | 3 |
| 17 | Open-Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed Therapy With Apremilast. | 5 |
| 18 | The Practice of Compounding, Associated Compounding Regulations, and the Impact on Dermatologists. | 6 |
| 19 | Rapid Onset of Action in Patients With Moderate-to-Severe Plaque Psoriasis With Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination. | 3 |
| 20 | 61 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.